Free Trial

Guardian Pharmacy Services (NYSE:GRDN) Stock Rating Lowered by Wall Street Zen

Guardian Pharmacy Services logo with Medical background

Key Points

  • Guardian Pharmacy Services has been downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, indicating a shift in analysts' outlook on the stock.
  • Truist Financial has increased its price target for Guardian Pharmacy Services from $28.00 to $30.00, while another analyst, Weiss Ratings, issued a "sell (d+)" rating.
  • The stock is currently trading at $23.92, with a market capitalization of $1.51 billion and a 12-month price range between $16.50 and $30.39.
  • Interested in Guardian Pharmacy Services? Here are five stocks we like better.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts also recently issued reports on GRDN. Weiss Ratings reissued a "sell (d+)" rating on shares of Guardian Pharmacy Services in a research report on Saturday, September 27th. Truist Financial upped their price target on Guardian Pharmacy Services from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, September 26th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $26.33.

Check Out Our Latest Analysis on GRDN

Guardian Pharmacy Services Price Performance

Shares of GRDN traded down $0.51 on Friday, reaching $23.92. The company's stock had a trading volume of 183,604 shares, compared to its average volume of 426,237. The stock's 50 day simple moving average is $25.02 and its two-hundred day simple moving average is $23.03. The stock has a market capitalization of $1.51 billion and a P/E ratio of -15.73. Guardian Pharmacy Services has a 12-month low of $16.50 and a 12-month high of $30.39.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC bought a new position in shares of Guardian Pharmacy Services during the first quarter worth $170,000. Parkside Financial Bank & Trust purchased a new position in shares of Guardian Pharmacy Services during the second quarter valued at about $41,000. Raymond James Financial Inc. bought a new stake in shares of Guardian Pharmacy Services in the second quarter worth about $43,000. Police & Firemen s Retirement System of New Jersey lifted its position in shares of Guardian Pharmacy Services by 76.8% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 2,444 shares of the company's stock worth $52,000 after buying an additional 1,062 shares in the last quarter. Finally, State of Wyoming bought a new position in Guardian Pharmacy Services during the second quarter valued at approximately $58,000.

About Guardian Pharmacy Services

(Get Free Report)

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Guardian Pharmacy Services Right Now?

Before you consider Guardian Pharmacy Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardian Pharmacy Services wasn't on the list.

While Guardian Pharmacy Services currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.